What is PTN's P/E ratio?

Palatin Technologies, Inc. Common Stock (PTN) currently trades at a P/E ratio of 3.05.

Palatin Technologies, Inc. Common Stock reports a Return on Equity (ROE) of -59.00%.

What is PTN's dividend yield?

Palatin Technologies, Inc. Common Stock offers a dividend yield of 0.00%.

What is PTN's Quality Score?

Our AI rates PTN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PTN?

Our AI Timing Score for PTN is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PTN belong to?

Palatin Technologies, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Palatin Technologies, Inc. (PTN) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

PTN AI Analysis Summary

Our AI summary for PTN: Palatin Technologies, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.05, ROE of -59.00%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PTN

Palatin Technologies, Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 7.94

-0.07 (-0.87%) Day Change

Watchlist Portfolio Compare Chart

3.05

P/E

0.02

D/E

-59.0%

ROE

-47.3%

ROA

0.00%

Div Yield

0.01

PEG

PALATIN TECHNOLOGIES, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.94 Price -0.07 (-0.87%) Day Change	NEWS SCORE: N/A

PTN, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

55%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	7.94
PBV / Sector	1.35 / 44,105.10 GOOD
Earning Per Share	-3.48

PE / Sector	3.05 / 19.37 GREAT
PEG or PE/Growth / Sector	0.01 / 1.06 GREAT
Average 1M Daily Value	0.09 M GREAT
Average 1W Daily Value	0.08 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-48.50 / 97.23
NPM Average (%) / Sector	-929.17 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-47.25 / 185,260.64
ROA Average (%) / Sector	-221.33 / 36,684.64
ROA Change Average (%) / Sector	33.81 / 422,221.42 GREAT
ROE (%) / Sector	-59.00 / 243,761.81
ROE Average (%) / Sector	5,628.83 / 48,758.38 GREAT
ROE Change Average (%) / Sector	217.57 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:32
Symbol	PTN
Name	PALATIN TECHNOLOGIES, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	1.78 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	14.25 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 11 Deer Park Drive, Monmouth Junction, NJ, United States, 08512

Phone: 609 495 2200

Website: https://palatin.com

Sector: Healthcare >> Biotechnology

Description: Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.